114 related articles for article (PubMed ID: 38006927)
1. The variability in CYP3A4 activity determines the metabolic kinetic characteristics of ketamine.
Li M; Li Q; Lin D; Zheng X; Jin L; Cai J; Hu G; Qian J
Toxicology; 2023 Dec; 500():153682. PubMed ID: 38006927
[TBL] [Abstract][Full Text] [Related]
2. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
[TBL] [Abstract][Full Text] [Related]
3. The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline.
Hu X; Ni J; Gao N; Ye Z; Hu G; Cai J; Qian J
Chem Biol Interact; 2022 Oct; 366():110123. PubMed ID: 36007633
[TBL] [Abstract][Full Text] [Related]
4. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
5. Gene Polymorphisms and Drug-Drug Interactions Determine the Metabolic Profile of Blonanserin.
Ye F; Li X; Ni J; Xu X; Luo J; Zhong Y; Wang Y; Wang S; Zhang Y; Hu G; Qian J
J Pharmacol Exp Ther; 2024 Jan; 388(1):190-200. PubMed ID: 37863485
[TBL] [Abstract][Full Text] [Related]
6. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
Li Q; Wang J; Wang ZL; Shen Y; Zhou Q; Liu YN; Hu GX; Cai JP; Xu RA
Biomed Pharmacother; 2023 Dec; 168():115833. PubMed ID: 37935069
[TBL] [Abstract][Full Text] [Related]
7. In vitro ketamine CYP3A-mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry.
Santamaria R; Pailleux F; Beaudry F
Biomed Chromatogr; 2014 Dec; 28(12):1660-9. PubMed ID: 24729431
[TBL] [Abstract][Full Text] [Related]
8. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.
Hijazi Y; Boulieu R
Drug Metab Dispos; 2002 Jul; 30(7):853-8. PubMed ID: 12065445
[TBL] [Abstract][Full Text] [Related]
9. Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.
Midde NM; Rahman MA; Rathi C; Li J; Meibohm B; Li W; Kumar S
PLoS One; 2016; 11(2):e0149225. PubMed ID: 26872388
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
11. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo.
Hu Y; Xie S; Xia H; Chen J; Yang Y; Zhan R
Toxicol Appl Pharmacol; 2024 Jan; 482():116797. PubMed ID: 38160892
[TBL] [Abstract][Full Text] [Related]
12. Microsomal cytochrome p450-mediated metabolism of protopanaxatriol ginsenosides: metabolite profile, reaction phenotyping, and structure-metabolism relationship.
Hao H; Lai L; Zheng C; Wang Q; Yu G; Zhou X; Wu L; Gong P; Wang G
Drug Metab Dispos; 2010 Oct; 38(10):1731-9. PubMed ID: 20639434
[TBL] [Abstract][Full Text] [Related]
13. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.
Yanagihara Y; Kariya S; Ohtani M; Uchino K; Aoyama T; Yamamura Y; Iga T
Drug Metab Dispos; 2001 Jun; 29(6):887-90. PubMed ID: 11353758
[TBL] [Abstract][Full Text] [Related]
14. Effect of flavonoids and CYP3A4 variants on midostaurin metabolism.
Xu RA; Li QQ; Gao NY; Wang J; Li XY; Ye F; Ni JH; Hu GX; Qian JC
Food Chem Toxicol; 2023 Apr; 174():113669. PubMed ID: 36805545
[TBL] [Abstract][Full Text] [Related]
15. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
16. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
Yanni SB; Annaert PP; Augustijns P; Ibrahim JG; Benjamin DK; Thakker DR
Drug Metab Dispos; 2010 Jan; 38(1):25-31. PubMed ID: 19841059
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS.
Xia M; Song X; Lu Z; Wang Y; Zhou Q; Geng P; Wang S; Zhou Y; Wu Q; Han A
Thorac Cancer; 2023 Nov; 14(33):3331-3341. PubMed ID: 37771131
[TBL] [Abstract][Full Text] [Related]
18. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Brandes LJ; Queen GM; LaBella FS
Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
[TBL] [Abstract][Full Text] [Related]
19. The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro.
Li Y; Coller JK; Hutchinson MR; Klein K; Zanger UM; Stanley NJ; Abell AD; Somogyi AA
Drug Metab Dispos; 2013 Jun; 41(6):1264-72. PubMed ID: 23550066
[TBL] [Abstract][Full Text] [Related]
20. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
Zhao K; Ding M; Cao H; Cao ZX
J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
